



February 20, 2015

Integra LifeSciences to Participate in the Raymond James Institutional Investors Conference, Barclays Global Healthcare Conference and the Canaccord Genuity Musculoskeletal Conference in March

PLAINSBORO, N.J., Feb. 20, 2015 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holdings Corporation](#) (Nasdaq:IART) today announced that it will present at the following conferences in March:

- At 7:30AM ET on Monday, March 2, 2015, Glenn Coleman, Chief Financial Officer, will present at the Raymond James Institutional Investors Conference in Orlando, Florida. This presentation will be webcast.
- At 10:45AM ET on Thursday, March 12, 2015, Robert T. Davis, Jr., CVP & President - Specialty Surgical Solutions, and Angela Steinway, Head of Investor Relations, will present at the Barclays Global Healthcare Conference in Miami, Florida. This presentation will be webcast.
- At 8:30AM PT on Tuesday, March 24, 2015, Glenn Coleman will present at the Canaccord Genuity Musculoskeletal Conference in Las Vegas, Nevada. This presentation will be webcast.

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies, and spine hardware and orthobiologics. For more information, please visit www.integralife.com

Statements made at the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2013 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Integra LifeSciences Holdings Corporation

Investor Relations:

Angela Steinway

(609) 936-2268

angela.steinway@integralife.com